Tesi etd-11192018-001159
Link copiato negli appunti
Tipo di tesi
Corsi integrativi di I livello
Autore
CASTIGLIONE, VINCENZO
URN
etd-11192018-001159
Titolo
Interleukin 33/Suppression of Tumorigenicity 2 Pathway in Cardiomyopathies
Struttura
Cl. Sc. Sperimentali - Medicina
Corso di studi
SCIENZE MEDICHE - Medicina e chirurgia (DM 270)
Commissione
Presidente Prof. RECCHIA, FABIO ANASTASIO
Relatore Prof. EMDIN, MICHELE
Membro Prof. PASSINO, CLAUDIO
Membro Dott.ssa ANGELONI, DEBORA
Membro Dott. MEOLA, MARIO
Membro Dott.ssa PETRUCCI, ILARIA
Membro Prof. COCEANI, FLAVIO
Relatore Prof. EMDIN, MICHELE
Membro Prof. PASSINO, CLAUDIO
Membro Dott.ssa ANGELONI, DEBORA
Membro Dott. MEOLA, MARIO
Membro Dott.ssa PETRUCCI, ILARIA
Membro Prof. COCEANI, FLAVIO
Parole chiave
- Cardiac amyloidosis
- Cardiomyopathy
- Dilated cardiomyopathy
- Hypertrophic cardiomyopathy
- sST2
Data inizio appello
12/12/2018;
Disponibilità
completa
Riassunto analitico
Background: Cardiomyopathies are a heterogeneous group of diseases characterized by structural and functional abnormalities of the ventricular myocardium, the most common being non-ischemic dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM) and cardiac amyloidosis. Left ventricular (LV) remodelling in cardiomyopathies determines gradual progression towards heart failure (HF). The interleukin-33 (IL-33)/suppression of tumorigenesis 2 (ST2) pathway exerts cardio-protective actions in response to myocardial stress, while soluble ST2 (sST2) acts as a decoy receptor for IL-33, blocking its favourable effects. sST2 concentrations have been recently found to correlate with left ventricular remodelling and worse outcome in HF patients.
Purpose: The main aim of this study is to compare three large populations of patients with primary cardiomyopathies, namely DCM, HCM, and cardiac amyloidosis, in relation to their baseline characteristics and plasma levels of sST2. The second aim of this study is to evaluate the diagnostic performance of sST2 in a subgroup of patients with signs of hypertrophy at cardiac imaging.
Methods: We retrospectively evaluated patients with DCM, HCM, and amyloidosis, referred at Fondazione Toscana Gabriele Monasterio (Pisa) for clinical management. Diagnosis of DCM, HCM, and amyloidosis was established according to most recent guidelines criteria. All patients underwent a comprehensive clinical assessment, a biohumoral characterization, and a transthoracic echocardiography. Chamber quantification and LGE assessment at CMR was also perfomred in a subgroup of patients.
Purpose: The main aim of this study is to compare three large populations of patients with primary cardiomyopathies, namely DCM, HCM, and cardiac amyloidosis, in relation to their baseline characteristics and plasma levels of sST2. The second aim of this study is to evaluate the diagnostic performance of sST2 in a subgroup of patients with signs of hypertrophy at cardiac imaging.
Methods: We retrospectively evaluated patients with DCM, HCM, and amyloidosis, referred at Fondazione Toscana Gabriele Monasterio (Pisa) for clinical management. Diagnosis of DCM, HCM, and amyloidosis was established according to most recent guidelines criteria. All patients underwent a comprehensive clinical assessment, a biohumoral characterization, and a transthoracic echocardiography. Chamber quantification and LGE assessment at CMR was also perfomred in a subgroup of patients.
File
| Nome file | Dimensione |
|---|---|
| Castiglione.pdf | 1.02 Mb |
Contatta l'autore |
|